Charles J Eyermann

List of Publications by Year
in descending order

18 papers	1,396 citations	516710 16 h-index	839539 18 g-index
18 all docs	18 docs citations	18 times ranked	1400 citing authors

#	Article	IF	Citations
1	X-ray Crystal Structures of Escherichia coli RNA Polymerase with Switch Region Binding Inhibitors Enable Rational Design of Squaramides with an Improved Fraction Unbound to Human Plasma Protein. Journal of Medicinal Chemistry, 2015, 58, 3156-3171.	6.4	36
2	Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa. Bioorganic and Medicinal Chemistry, 2014, 22, 5392-5409.	3.0	26
3	Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG Activity. Journal of Medicinal Chemistry, 2011, 54, 7834-7847.	6.4	101
4	Novel Substituted (Pyridin-3-yl)phenyloxazolidinones:â€‰ Antibacterial Agents with Reduced Activity against Monoamine Oxidase A and Increased Solubility. Journal of Medicinal Chemistry, 2007, 50, 4868-4881.	6.4	38
5	Identification of 4-Substituted 1,2,3-Triazoles as Novel Oxazolidinone Antibacterial Agents with Reduced Activity against Monoamine Oxidase A. Journal of Medicinal Chemistry, 2005, 48, 499-506.	6.4	282
6	Structure-based design of novel nonpeptide inhibitors of the Src SH2 domain: Phosphotyrosine mimetics exploiting multifunctional group replacement chemistry*. Biopolymers, 2003, 71, 717-729.	2.4	16
7	Src Homology-2 Inhibitors: Peptidomimetic and Nonpeptide. Mini-Reviews in Medicinal Chemistry, 2002, 2, 475-488.	2.4	58
8	A novel phosphotyrosine mimetic 4â€²-carboxymethyloxy-3â€²-phosphonophenylalanine (cpp): exploitation in the design of nonpeptide inhibitors of pp60Src SH2 domain. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2319-2323.	2.2	28
9	Nonpeptide Cyclic Cyanoguanidines as HIV-1 Protease Inhibitors:Â Synthesis, Structureâ^'Activity Relationships, and X-ray Crystal Structure Studies. Journal of Medicinal Chemistry, 1998, 41, 1446-1455.	6.4	55
10	Calculated and Experimental Low-Energy Conformations of Cyclic Urea HIV Protease Inhibitors. Journal of the American Chemical Society, 1998, 120, 4570-4581.	13.7	48
11	Molecular Recognition of Cyclic Urea HIV-1 Protease Inhibitors. Journal of Biological Chemistry, 1998, 273, 12325-12331.	3.4	40
12	The role of computer-aided and structure-based design techniques in the discovery and optimization of cyclic urea inhibitors of hiv protease. Advances in Amino Acid Mimetics and Peptidomimetics, 1997, , 1-40.	0.3	8
13	Cyclic HIV Protease Inhibitors:Â Synthesis, Conformational Analysis, P2/P2â€˜ Structureâ^'Activity Relationship, and Molecular Recognition of Cyclic Ureas. Journal of Medicinal Chemistry, 1996, 39, 3514-3525.	6.4	182
14	Design, synthesis and in vitro activities of a series of benzimidazole/benzoxazole glycoprotein IIb/IIIa inhibitors. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 339-344.	2.2	24
15	Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chemistry and Biology, 1996, 3, 301-314.	6.0	136
16	NMR and X-ray Evidence That the HIV Protease Catalytic Aspartyl Groups Are Protonated in the Complex Formed by the Protease and a Non-Peptide Cyclic Urea-Based Inhibitor. Journal of the American Chemical Society, 1994, 116, 10791-10792.	13.7	127
17	NMR Evidence for the Displacement of a Conserved Interior Water Molecule in HIV Protease by a Non-Peptide Cyclic Urea-Based Inhibitor. Journal of the American Chemical Society, 1994, 116, 1581-1582.	13.7	61
18	Structural Studies of a Family of High Affinity Ligands for GPIIb/IIIa. Journal of the American Chemical Society, 1994, 116, 3207-3219.	13.7	130